These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Freeman A; Horner T; Pendleton RC; Rondina MT Am J Hematol; 2012 Jul; 87(7):740-3. PubMed ID: 22565589 [TBL] [Abstract][Full Text] [Related]
4. A Weight- and Anti-Xa-Guided Enoxaparin Dosing Protocol for venous thromboembolism Prophylaxis in intensive care unit Trauma Patients. Bigos R; Solomon E; Dorfman JD; Ha M J Surg Res; 2021 Sep; 265():122-130. PubMed ID: 33930618 [TBL] [Abstract][Full Text] [Related]
5. Dose adjusting enoxaparin is necessary to achieve adequate venous thromboembolism prophylaxis in trauma patients. Costantini TW; Min E; Box K; Tran V; Winfield RD; Fortlage D; Doucet J; Bansal V; Coimbra R J Trauma Acute Care Surg; 2013 Jan; 74(1):128-33; discussion 134-5. PubMed ID: 23271087 [TBL] [Abstract][Full Text] [Related]
6. Association of Anti-Factor Xa-Guided Dosing of Enoxaparin With Venous Thromboembolism After Trauma. Karcutskie CA; Dharmaraja A; Patel J; Eidelson SA; Padiadpu AB; Martin AG; Lama G; Lineen EB; Namias N; Schulman CI; Proctor KG JAMA Surg; 2018 Feb; 153(2):144-149. PubMed ID: 29071333 [TBL] [Abstract][Full Text] [Related]
7. Implementation of an enoxaparin protocol for venous thromboembolism prophylaxis in obese surgical intensive care unit patients. Ludwig KP; Simons HJ; Mone M; Barton RG; Kimball EJ Ann Pharmacother; 2011 Nov; 45(11):1356-62. PubMed ID: 22009998 [TBL] [Abstract][Full Text] [Related]
9. Enoxaparin dosing after cesarean delivery in morbidly obese women. Overcash RT; Somers AT; LaCoursiere DY Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508 [TBL] [Abstract][Full Text] [Related]
10. Single-center Experience with Venous Thromboembolism Prophylaxis for Obese Burn Patients. McKinzie BP; Nizamani R; Jones S; King B; Williams FN J Burn Care Res; 2021 May; 42(3):365-368. PubMed ID: 33674883 [TBL] [Abstract][Full Text] [Related]
11. Enoxaparin Thromboprophylaxis Dosing and Anti-Factor Xa Levels in Low-Weight Patients. Yam L; Bahjri K; Geslani V; Cotton A; Hong L Pharmacotherapy; 2019 Jul; 39(7):749-755. PubMed ID: 31112313 [TBL] [Abstract][Full Text] [Related]
12. Weight-Based Dosing for Once-Daily Enoxaparin Cannot Provide Adequate Anticoagulation for Venous Thromboembolism Prophylaxis. Pannucci CJ; Hunt MM; Fleming KI; Prazak AM Plast Reconstr Surg; 2017 Oct; 140(4):815-822. PubMed ID: 28953735 [TBL] [Abstract][Full Text] [Related]
13. Association Between Enoxaparin Dosage Adjusted by Anti-Factor Xa Trough Level and Clinically Evident Venous Thromboembolism After Trauma. Ko A; Harada MY; Barmparas G; Chung K; Mason R; Yim DA; Dhillon N; Margulies DR; Gewertz BL; Ley EJ JAMA Surg; 2016 Nov; 151(11):1006-1013. PubMed ID: 27383732 [TBL] [Abstract][Full Text] [Related]
14. Increased enoxaparin dosing is required for obese children. Lewis TV; Johnson PN; Nebbia AM; Dunlap M Pediatrics; 2011 Mar; 127(3):e787-90. PubMed ID: 21321026 [TBL] [Abstract][Full Text] [Related]
15. Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding. Pannucci CJ; Fleming KI; Momeni A; Prazak AM; Agarwal J; Rockwell WB Plast Reconstr Surg; 2018 Jun; 141(6):1580-1590. PubMed ID: 29608533 [TBL] [Abstract][Full Text] [Related]
16. Multicenter study evaluating target attainment of anti-Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients. Chanas T; Gibson G; Langenstroer E; Herrmann DJ; Carver TW; Alexander K; Chui SHJ; Rein L; Ha M; Maynard KM; Bamberg K; O'Keefe M; O'Brien M; Gonzalez MC; Hobbs B; Pajoumand M; Peppard WJ Pharmacotherapy; 2024 Mar; 44(3):258-267. PubMed ID: 38148134 [TBL] [Abstract][Full Text] [Related]
17. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients. Walker CK; Sandmann EA; Horyna TJ; Gales MA Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055 [TBL] [Abstract][Full Text] [Related]
18. Higher doses of low-molecular-weight heparin (enoxaparin) are needed to achieve target anti-Xa concentrations in critically ill children*. Schloemer NJ; Abu-Sultaneh S; Hanson SJ; Yan K; Hoffmann RG; Punzalan RC; Havens PL Pediatr Crit Care Med; 2014 Sep; 15(7):e294-9. PubMed ID: 24901803 [TBL] [Abstract][Full Text] [Related]
19. Stratifying Therapeutic Enoxaparin Dose in Morbidly Obese Patients by BMI Class: A Retrospective Cohort Study. Lee YR; Palmere PJ; Burton CE; Benavides TM Clin Drug Investig; 2020 Jan; 40(1):33-40. PubMed ID: 31625111 [TBL] [Abstract][Full Text] [Related]
20. Weight-Based Enoxaparin for Venous Thromboembolism in Obesity Gives Similar Anti-Xa Levels to Patients <100 kg, with No Increase in Major Bleeding. Maclachlan KH; Stevens HP; Tran HA; Chunilal SD Semin Thromb Hemost; 2019 Feb; 45(1):94-99. PubMed ID: 30630208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]